The deal provides Natco with the certainty of a generic Revlimid launch in the US as well as a billion-dollar windfall
Hyderabad: Natco Pharma Ltd and partner Allergan Plc on Wednesday reached a settlement with US-based drug maker Celgene Corp. in the patent infringement case of the latter’s blockbuster cancer drug Revlimid.
Recommended For You
Select your Category
Internet Not Available
Wait for it…
Log in to our website to save your bookmarks. It'll just take a moment.